EU And U.S. Regulators Toughen CV Monitoring Requirements For Novartis's Gilenya

A review of a potential association between Novartis's oral multiple sclerosis therapy Gilenya and sudden death was inconclusive, say EU regulators, but monitoring requirements are still strengthened as a precaution.